Lista de obras - Gordon C. Jayson - Dominio Público Uruguay

A Longitudinal Investigation of Psychological Disorders in Patients Prior and Subsequent to a Diagnosis of Ovarian Cancer

scientific article published on 01 June 2010

A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides

artículo científico publicado en 2015

A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer

artículo científico publicado en 2010

A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition

artículo científico publicado en 2019

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

artículo científico publicado en 2013

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

artículo científico publicado en 2007

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

artículo científico publicado en 2010

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

artículo científico publicado en 1995

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

artículo científico publicado en 2011

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

artículo científico publicado en 2001

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

artículo científico publicado en 2003

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

artículo científico publicado en 2004

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

artículo científico publicado en 1998

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

artículo científico publicado en 2010

Accessing cancer services in North West England: the Chinese population.

artículo científico publicado en 2014

Alpha-v integrins as therapeutic targets in oncology.

scientific article published on October 2007

An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer

artículo científico publicado en 2018

An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre.

artículo científico publicado en 1999

Angiogenese-Hemmung durch Proteine, Peptide und «small molecules»: Klinischer Einsatz

scientific article published on 03 October 2005

Angiogenesis as a target for the treatment of ovarian cancer

artículo científico

Angiogenesis as a therapeutic target in cancer

scientific article published on 01 August 2008

Antiangiogenic drugs in ovarian cancer.

artículo científico publicado en 2009

Antiangiogenic therapy in oncology: current status and future directions

artículo científico publicado en 2016

Antiangiogenic therapy--evolving view based on clinical trial results

artículo científico publicado en 2012

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

artículo científico publicado en 2018

Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.

artículo científico publicado en 2003

Basic fibroblast growth factor increases the multiplication and migration of a serum-free derivative of CACO-2 but does not affect differentiation

scientific article published on 01 November 1994

Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer

artículo científico publicado en 2008

Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates.

artículo científico publicado en 2003

Biomarkers and response to bevacizumab--response

artículo científico publicado en 2014

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

artículo científico publicado en 2010

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

artículo científico publicado en 2004

Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model

artículo científico publicado en 2002

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

artículo científico publicado en 1998

Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant

scientific article published on 01 December 1994

Carcinomatous meningitis in solid tumours

artículo científico publicado en 1996

Carcinosarcoma of the ovary.

artículo científico publicado en 2003

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

artículo científico publicado en 2016

Chemotherapy for ovarian cancer--a consensus statement on standard practice. ⬇️

artículo científico publicado en 1998

Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen

artículo científico publicado en 2009

Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement.

artículo científico publicado en 2006

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma

artículo científico publicado en 1995

Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma

artículo científico publicado en 1999

Cross-Visit Tumor Sub-segmentation and Registration with Outlier Rejection for Dynamic Contrast-Enhanced MRI Time Series Data

artículo científico publicado en 2010

DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease

artículo científico publicado en 2011

Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition

artículo científico publicado en 2020

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

artículo científico publicado en 2005

Development of antiangiogenic agents for ovarian cancer.

artículo científico publicado en 2008

Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision

scientific article published on 07 January 2020

Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors? ⬇️

artículo científico publicado el 23 de octubre de 2012

Doctor, does this mean I'm going to starve to death?

artículo científico publicado en 2004

Does clinical trial participation improve outcomes in patients with ovarian cancer?

artículo científico publicado en 2016

Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer

scientific article published on 23 January 2019

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

artículo científico publicado en 2012

Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients

artículo científico publicado en 2019

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

artículo científico publicado en 2010

Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor.

artículo científico publicado en 2012

Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

artículo científico publicado en 2007

Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer

artículo científico publicado en 2014

Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

artículo científico publicado en 2006

First gram-scale synthesis of a heparin-related dodecasaccharide.

artículo científico publicado en 2012

Heparan sulfate proteoglycans and cancer.

artículo científico publicado en 2001

Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro

artículo científico publicado en 1998

Heparan sulphate synthetic and editing enzymes in ovarian cancer

artículo científico publicado en 2007

Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma

article

Heparin octasaccharides inhibit angiogenesis in vivo.

artículo científico publicado en 2005

High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique ⬇️

artículo científico publicado el 8 de mayo de 1998

Home parenteral nutrition for people with inoperable malignant bowel obstruction

Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies

artículo científico publicado en 2004

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

artículo científico publicado en 2010

Imaging angiogenesis of genitourinary tumors.

artículo científico publicado en 2010

Imaging biomarker roadmap for cancer studies ⬇️

artículo científico publicado en 2016

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

artículo científico publicado en 2007

Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro

artículo científico publicado en 1994

Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor

artículo científico publicado en 2005

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. ⬇️

artículo científico publicado en 2016

Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: application to dynamic contrast-enhanced MRI biomarkers

artículo científico publicado en 2014

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

artículo científico publicado en 2010

Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.

artículo científico publicado en 2010

Intra-tumoural microvessel density in human solid tumours.

artículo científico publicado en 2002

Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

artículo científico

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

artículo científico publicado en 2010

Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer

artículo científico publicado en 2007

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

scientific article published on 10 July 2020

Malignant bowel obstruction in advanced ovarian cancer.

artículo científico publicado en 2017

Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance

artículo científico publicado en 2000

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

artículo científico publicado en 2006

Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.

artículo científico publicado en 2014

Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential o-6 protections: programming for regiodefined 6-o-modifications.

artículo científico publicado en 2015

Molecular imaging of antiangiogenic agents.

artículo científico publicado en 2005

Molecular phenotyping of a UK population: defining the human serum metabolome

artículo científico publicado en 2015

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

artículo científico publicado en 2018

Novel Anti-angiogenic Therapies in Ovarian Cancer

Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial

artículo científico publicado en 2019

Oligosaccharides as anti-angiogenic agents

scientific article published on 01 March 2008

Oral melphalan as a treatment for platinum-resistant ovarian cancer.

scientific article published on June 2003

Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times

artículo científico publicado en 2007

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube

artículo científico publicado en 2011

Ovarian cancer

scholarly article

Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling

artículo científico publicado en 2014

PARP inhibitors in BRCA mutation-associated ovarian cancer

artículo científico publicado en 2014

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

artículo científico publicado en 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

artículo científico publicado en 2003

Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers

artículo científico publicado en 2019

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial

artículo científico publicado en 2020

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

artículo científico publicado en 2016

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

artículo científico publicado en 2007

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

artículo científico publicado en 2007

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

scientific article published on 22 January 2005

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

artículo científico publicado en 2011

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

artículo científico publicado en 2005

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

artículo científico publicado en 2004

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

artículo científico publicado en 2018

Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics.

artículo científico publicado en 2005

Pre-operative Plasma Levels of Vascular Endothelial Growth Factor A, C and D in Patients with Colorectal Cancer

artículo científico publicado en 2005

Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone

artículo científico publicado en 2005

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection

artículo científico publicado en 2013

Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors

artículo científico publicado en 2009

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases

scientific article published on 25 January 2019

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

artículo científico publicado en 2015

Profiling heparan sulfate proteoglycans in ovarian carcinoma

artículo científico publicado en 2005

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

artículo científico publicado en 2009

Quantifying heterogeneity in dynamic contrast-enhanced MRI parameter maps

artículo científico publicado en 2007

Quantitative angiogenesis assays in vivo--a review.

artículo científico publicado en 2004

Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives

artículo científico publicado en 2008

Quantitative multiplexed quantum dot immunohistochemistry.

artículo científico publicado en 2008

Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.

artículo científico publicado en 2000

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

artículo científico publicado en 2011

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

artículo científico publicado en 2005

Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium

artículo científico publicado en 2005

Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma

artículo científico publicado en 2003

Requirement for expert histopathological assessment of ovarian cancer and borderline tumors

artículo científico publicado en 2000

Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes

artículo científico publicado en 1997

Scalable Synthesis ofl-Iduronic Acid Derivatives via Stereocontrolled Cyanohydrin Reaction for Synthesis of Heparin-Related Disaccharides

artículo científico publicado en 2009

Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer

artículo científico publicado en 2019

Segregation of late outgrowth endothelial cells into functional endothelial CD34- and progenitor-like CD34+ cell populations

artículo científico publicado en 2014

Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.

artículo científico publicado en 1997

Small-molecule-induced clustering of heparan sulfate promotes cell adhesion.

artículo científico publicado en 2013

Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study

artículo científico publicado en 2004

Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center

artículo científico publicado en 2006

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial ⬇️

artículo científico publicado en 2015

Synthesis and scalable conversion of L-iduronamides to heparin-related di- and tetrasaccharides

artículo científico publicado en 2012

Synthesis of a heparin-related GlcN-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy

artículo científico publicado en 2014

Synthesis of l-Iduronic Acid Derivatives via [3.2.1] and [2.2.2] l-Iduronic Lactones from Bulk Glucose-Derived Cyanohydrin Hydrolysis: A Reversible Conformationally Switched Superdisarmed/Rearmed Lactone Route to Heparin Disaccharides

artículo científico publicado en 2015

Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo

artículo científico publicado en 2016

Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.

artículo científico publicado en 2015

Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis

artículo científico publicado en 2010

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab ⬇️

artículo científico publicado en 2016

Targeted anti-vascular therapies for ovarian cancer: current evidence ⬇️

artículo científico publicado en 2013

Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.

artículo científico publicado en 2005

The Best Guess Approach to Phase I Trial Design

article

The Neoadjuvant Approach in the Treatment of Patients with Advanced Epithelial Ovarian Carcinoma

artículo científico publicado en 2007

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

artículo científico publicado en 2005

The clinical potential of antiangiogenic fragments of extracellular matrix proteins

artículo científico publicado en 2005

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

artículo científico publicado en 2014

The development of anti-angiogenic heparan sulfate oligosaccharides

artículo científico publicado en 2014

The ethical and scientific case for phase 2C clinical trials

artículo científico publicado en 2010

The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma

artículo científico publicado en 2006

The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate

artículo científico publicado en 2006

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone ⬇️

artículo científico publicado el 1 de septiembre de 1998

Thrombosis in ovarian cancer: a case control study.

artículo científico publicado en 2014

VEGF inhibitors and advanced ovarian cancer

artículo científico publicado en 2011

Vascular Endothelial Growth Factor Antagonists as Anticancer Agents

Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy.

artículo científico publicado en 2003

Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy

artículo científico publicado en 2006

Weekly paclitaxel in the treatment of recurrent ovarian carcinoma

artículo científico publicado en 2007

Weekly platinum chemotherapy for recurrent ovarian cancer

artículo científico publicado en 2002

p53 And related proteins in epithelial ovarian cancer

artículo científico publicado en 2000

Lista de obras de Gordon C. Jayson

A Longitudinal Investigation of Psychological Disorders in Patients Prior and Subsequent to a Diagnosis of Ovarian Cancer

A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides

A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer

A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

Accessing cancer services in North West England: the Chinese population.

Alpha-v integrins as therapeutic targets in oncology.

An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer

An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre.

Angiogenese-Hemmung durch Proteine, Peptide und «small molecules»: Klinischer Einsatz

Angiogenesis as a target for the treatment of ovarian cancer

Angiogenesis as a therapeutic target in cancer

Antiangiogenic drugs in ovarian cancer.

Antiangiogenic therapy in oncology: current status and future directions

Antiangiogenic therapy--evolving view based on clinical trial results

Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer

Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.

Basic fibroblast growth factor increases the multiplication and migration of a serum-free derivative of CACO-2 but does not affect differentiation

Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer

Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates.

Biomarkers and response to bevacizumab--response

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant

Carcinomatous meningitis in solid tumours

Carcinosarcoma of the ovary.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Chemotherapy for ovarian cancer--a consensus statement on standard practice. ⬇️

Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen

Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement.

Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma

Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma

Cross-Visit Tumor Sub-segmentation and Registration with Outlier Rejection for Dynamic Contrast-Enhanced MRI Time Series Data

DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease

Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

Development of antiangiogenic agents for ovarian cancer.

Discharging Women with Advanced Ovarian Cancer on Home Parenteral Nutrition: Making and Implementing the Decision

Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors? ⬇️

Doctor, does this mean I'm going to starve to death?

Does clinical trial participation improve outcomes in patients with ovarian cancer?

Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor.

Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer

Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

First gram-scale synthesis of a heparin-related dodecasaccharide.

Heparan sulfate proteoglycans and cancer.

Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro

Heparan sulphate synthetic and editing enzymes in ovarian cancer

Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma

Heparin octasaccharides inhibit angiogenesis in vivo.

High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique ⬇️

Home parenteral nutrition for people with inoperable malignant bowel obstruction

Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

Imaging angiogenesis of genitourinary tumors.

Imaging biomarker roadmap for cancer studies ⬇️

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro

Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. ⬇️

Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: application to dynamic contrast-enhanced MRI biomarkers

Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.